ANSTO

8 February 2022

ANSTO is in the process of constructing the SyMo facility which is intended to utilise SYNROC technology to immobilise waste from ANSTO’s Mo-99 production processes.

Clipboard
29 October 2021

On 29 June 2018, the ARPANSA CEO issued a Direction to ANSTO to initiate an independent safety review following a series of events with safety implications at the ANSTO Health (now Health Products) facility. ARPANSA has been monitoring progress against the implementation plan and is generally satisfied with the actions taken to date.

27 January 2021
Inspection report details
Clipboard icon with checkbox
31 March 2020

On 27 March 2020, the CEO of ARPANSA, Dr Carl-Magnus Larsson, removed a licence condition from the ANSTO Nuclear Medicine (ANM) facility, allowing it to return to routine operation.

Clipboard icon with checkbox
6 December 2019

In June 2018, ARPANSA issued a direction to its licence holder, the Australian Nuclear Science and Technology Organisation (ANSTO), to initiate an independent review of its approach to occupational radiation safety at its nuclear medicine facility operated by ANSTO Health, now known as Health Products.

Clipboard
26 June 2019

On Friday 21 June 2019, ARPANSA was notified of a radiation contamination event at the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine (ANM) production facility in Lucas Heights, New South Wales.

Clipboard icon with checkbox
27 May 2019

ARPANSA’s CEO, Dr Carl-Magnus Larsson has amended a licence issued to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine (ANM) facility.

Clipboard icon with checkbox
8 April 2019

ARPANSA has granted the Australian Nuclear Science and Technology Organisation (ANSTO) an amended license to allow for the limited production of molybdenum-99 in order to sustain supply.

Pages

Subscribe to RSS - ANSTO